Case report: Treatment with ensartinib shows good response to SQSTM1-ALK fusion in lung adenocarcinoma

Case report: Treatment with ensartinib shows good response to SQSTM1-ALK fusion in lung adenocarcinoma

Lung cancer is a prevalent malignancy, with the rearrangement of the anaplastic lymphoma kinase (ALK) gene being responsible for a minority of cases of non-small cell lung cancer (NSCLC). NSCLC patients harboring ALK fusion proteins demonstrate sensitivity to ALK tyrosine kinase inhibitors (TKIs). I...

Full description

Bibliographic Details
Main Authors: Pandeng Wang, Zhuo Jiang, Jianji Guo, Tao Liu, Zhen Liu, Dongdong Wang, Honglin Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Pharmacology
Subjects:
SQSTM1-ALK
rearrangement
lung cancer
targeted therapy
ensartinib
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1433894/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1433894/full

Similar Items